For Intercept Pharmaceuticals’ beleaguered liver disease drug Ocaliva, the hits just keep coming. Ahead of an advisory committee meeting slated for Friday, the FDA on Wednesday unleashed damning ...

While the path for any drug to go from lab research to commercialization takes years, Intercept Pharmaceuticals now stands as another example that a product’s market exit can also be long and winding.

After a long run of regulatory stumbles and the recent withdrawal of its lone commercial drug from the U.S. market, Intercept Pharmaceuticals is implementing a restructuring and rounds of job cuts in ...